Communiqués ME Therapeutics Holdings Inc.

Actions

METX

CA5527671054

Recherche biotechnologique et médicale

Temps Différé Canadian Securities Exchange 19:49:32 18/08/2026			Varia. 5j.	Varia. 1 janv.
1,750 ^CAD	0,00%		-30,00%	-56,25%

17/07	ME Therapeutics lève 0,58 million de dollars canadiens via un placement privé sans intermédiaire	MT
26/06	ME Therapeutics Holdings Inc. publie ses résultats pour le troisième trimestre et les neuf mois clos le 31 mai 2026	CI

Communiqués

04/06	ME Therapeutics Announces Private Placement	AQ
07/05	ME Therapeutics to Pitch at CSE Capital Tech Connect During Web Summit Vancouver	BU
29/04	ME Therapeutics Provides Scientific Update on In Vivo CAR and Therapeutic mRNA Programs	BU
30/01	ME Therapeutics Scientific and Corporate Update	BU
06/01	ME Therapeutics Attending JP Morgan Healthcare Conference	BU
16/10/25	ME Therapeutics Granted Licence for CD22 Nanobody Asset to Expand Next-Gen In Vivo CAR Cell Therapy Program	BU
13/10/25	ME Therapeutics Added to CSE25 Index	AQ
10/10/25	ME Therapeutics Added to CSE25 Index	BU
29/09/25	ME Therapeutics Secures U.S. Patent for Lead Candidate and Advances Broader Therapeutic Programs	AQ
26/09/25	Canadian Investment Regulatory Organization Trade Resumption - METX	AQ
26/09/25	ME Therapeutics Secures U.S. Patent for Lead Candidate and Advances Broader Therapeutic Programs	BU
26/09/25	Canadian Investment Regulatory Organization Trading Halt - METX	AQ
21/05/25	ME Therapeutics Receives Support to Advance mRNA Therapeutic Candidates for Cancer and Inflammatory Disease	BU
03/03/25	ME Therapeutics Announces It Has Engaged Lucosky Brookman LLP to Explore a Listing on the NASDAQ or NYSE	NE
14/01/25	ME Therapeutics Announces That Its First Therapeutic mRNA Candidate Shows Encouraging Anti-Cancer Efficacy in Vivo	NE
25/10/24	ME Therapeutics Holdings Inc. Appoints Chief Business Officer	NE
22/10/24	ME Therapeutics Holdings Inc. Provides Research and Development Update and Corporate Update	NE
18/09/24	ME Therapeutics Announces the Start of Testing of First mRNA Formulations from NanoVation Therapeutics Collaboration	NE
08/07/24	ME Therapeutics Announces New Collaboration with NanoVation Therapeutics on Advanced Therapeutic mRNA Delivery to Myeloid Cells	NE
29/05/24	ME Therapeutics Holdings Inc. Announces the Addition of Two New Clinical Consultants to Continue the Advancement of Our Lead Anti-G-CSF Antibody Candidate Towards a First-in-Human Clinical Trial	NE
17/05/24	ME Therapeutics to Present at Investor Clubhouse at the Canadian Open and Attend the 2024 BIO International Convention for Partnering Opportunities	NE
15/04/24	ME Therapeutics Holdings Inc. Announces Ringing of CSE Opening Bell on April 17, 2024	NE
26/03/24	ME Therapeutics Holdings Inc. Announces Upcoming Participation in the 2024 Bloom Burton & Co Health Care Conference and Interview On CSE TV	NE
06/03/24	ME Therapeutics Announces Closing of Non-Brokered Private Placement	NE
27/02/24	ME Therapeutics Announces Non-Brokered Private Placement and Provides Corporate Update	NE